Compare Adaptive Biotechnologies Corp (ADPT) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Gold Fields Limited — how do they compare? Adaptive Biotechnologies Corp trades at $24.98 (market cap $4.04B), while Gold Fields Limited trades at $40.67 (market cap $36.07B). The key difference: Gold Fields Limited is far larger — about 8.9× Adaptive Biotechnologies Corp's market cap, and Gold Fields Limited pays a 5.76% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GFI | |
|---|---|---|
Market Cap | $4.04B | $36.07B |
Sector | Health | Basic Materials |
52-Week High | $25.45 | $61.52 |
52-Week Low | $12.30 | $29.31 |
Enterprise Value | $4.10B | $37.51B |
Dividend Yield | — | 5.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Gold Fields (GFI) trades at $41.06, down 0.16% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong fundamentals with a P/E of 10.22, net income margin of 40.76%, and robust cash flow growth, with 2025 projections indicating revenue of $8.8B and net income of $3.6B. Recent news highlights institutional buying interest, such as Assenagon Asset Management's new position in Q2 2026.
The outlook for GFI is positive, supported by high profitability and growth projections, though risks include volatile gold prices and cost pressures. Analyst consensus is a Buy with a $52 price target, suggesting 27% upside. Investors should weigh strong cash generation against debt increases and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
